natgillin/translations-raw huggingface dataset:
After the first vaccination course, a booster should be given, preferably before the end of the second year of life. 
Po končanem osnovnem cepljenju je potrebno opraviti obnovitveno cepljenje, po možnosti pred dopolnjenim drugim letom starosti.
Quintanrix should not be used in people who may be hypersensitive (allergic) to any of the active substances or any of the other ingredients. 
Cepiva Quintanrix ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) zdravilne učinkovine ali katerokoli drugo sestavino cepiva.
The recommended vaccination schedule for Quintanrix is three doses, given at intervals of at least four weeks within the first six months of life. 
Priporočena shema cepljenja za cepivo Quintanrix je sestavljena iz treh odmerkov, ki se jih daje v prvih šestih mesecih življenja s časovnimi presledki najmanj 4 tedne.
Quintanrix can be given to children who received a hepatitis B vaccine at birth. 
Cepivo Quintanrix se lahko daje otrokom, ki so prejeli cepivo proti hepatitisu B ob rojstvu.
Quintanrix contains small amounts of: 
Cepivo Quintanrix vsebuje majhne količine:
What benefit has Quintanrix shown during the studies? 
Kakšne koristi je zdravilo Quintanrix izkazalo med študijami?
The most common side effects with Quintanrix (seen in more than 1 in 10 doses of the vaccine) are irritability, drowsiness, loss of appetite, pain, redness and swelling, and fever. 
Najpogostejši neželeni učinki cepiva Quintanrix (opaženi pri več kot 1 od 10 odmerkov cepiva) so razdražljivost, zaspanost, izguba apetita, bolečine, pordelost, otekanje in zvišana telesna temperatura.
• polysaccharides extracted from the ‘capsules' that surround the bacterium Hib - the polysaccharides are chemically attached (conjugated) to tetanus toxoid as a carrier protein because this improves the response to the vaccine; 
• polisaharide iz kapsule, ki obdaja bakterijo Hib - polisaharidi so kemijsko vezani (konjugirani) na tetanusni toksoid, ki deluje kot nosilna beljakovina, saj to izboljša odziv na cepivo,
Quintanrix should be postponed in people with a severe sudden fever. 
Cepljenje s cepivom Quintanrix je treba odložiti pri osebah s hudo, nenadno zvišano telesno temperaturo.
The fourth study compared the effects of Quintarix given at six, 10 and 14 weeks of age in 318 infants who either had or had not received a hepatitis B vaccine at birth. 
V četrti študiji so primerjali učinke cepiva Quintanrix, uporabljenega pri šestih, 10 in 14 tednih starosti pri 318 dojenčkih, ki so prejeli cepivo proti hepatitisu B ob rojstvu ali pa ne.
The study of booster vaccination also showed Quintanrix was as effective as the two separate vaccines, with between 92 and 100% of the infants having protective levels of antibodies 42 days after the booster vaccination. 
Študija obnovitvenega cepljenja je pokazala, da je cepivo Quintanrix enako učinkovito kot dve ločeni cepivi, saj je imelo 42 dni po obnovitvenem cepljenju od 92 do 100 % otrok zaščitne ravni protiteles.
The first dose can be administered at six weeks of age. 
Otrok lahko prejme prvi odmerek cepiva pri 6 tednih starosti.
It contains the following active substances: toxoids (chemically weakened toxins) from diphtheria and tetanus, inactivated (killed) Bordetella pertussis (a bacterium that causes whooping cough), parts of the hepatitis B virus and polysaccharides (sugars) from the bacterium Haemophilus influenzae type b (‘Hib', a bacterium that causes meningitis). 
Cepivo vsebuje naslednje zdravilne učinkovine: toksoida (kemijsko oslabljena toksina) iz bakterij, ki povzročata davico in tetanus, inaktivirano (uničeno) bakterijo Bordetella pertussis (bakterijo, ki povzroča oslovski kašelj), dele virusa hepatitisa B in polisaharide (sladkorje) iz bakterije Haemophilus influenzae tipa b („Hib“, bakterije, ki povzroča meningitis).
The active substances in Quintanrix have been available in the European Union (EU) for a number of years in other vaccines: diphtheria, tetanus, pertussis and hepatitis B, has been available in Tritanrix HepB since 1996. 
Zdravilne učinkovine v cepivu Quintanrix so bile na voljo v Evropski uniji (EU) že več let v drugih cepivih: učinkovine proti davici, tetanusu, oslovskemu kašlju in hepatitisu B so bile na voljo v cepivu Tritanrix HepB od leta 1996.
For the full list of side effects reported with Quintanrix, see the Package Leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi cepiva Quintanrix, glejte navodilo za uporabo.
As for all vaccines, if Quintanrix is used in very premature babies, there is a risk of the babies experiencing apnoea (brief pauses in breathing). 
Če cepivo Quintanrix kot tudi vsa cepiva uporabimo pri veliko prezgodaj rojenih nedonošenčkih, obstaja tveganje pojava apneje (kratkih prekinitev dihanja).
What is the risk associated with Quintanrix? 
Kakšna tveganja so povezana z zdravilom Quintanrix?
Why has Quintanrix been approved? 
Zakaj je bilo zdravilo Quintanrix odobreno?
The Committee for Medicinal Products for Human Use (CHMP) decided that Quintanrix's benefits are greater than its risks for primary immunisation of infants (during the first year of life) against diphtheria, tetanus, pertussis, hepatitis B and invasive disease caused by Hib and for booster immunisation of young children during the second year of life. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi cepiva Quintanrix večje od z njim povezanih tveganj primarnega cepljenja dojenčkov (med prvim letom starosti) proti davici, tetanusu, oslovskemu kašlju, hepatitisu B in invazivni bolezni, ki jo povzroči Hib, in tveganj obnovitvenega cepljenja majhnih otrok med drugim letom starosti.
Quintarix was as effective as the two separate vaccines at producing protective levels of antibodies. 
Cepivo Quintanrix je enako učinkovito spodbudilo nastanek zaščitnih ravni protiteles kot ločeni cepivi.
Quintanrix is used to vaccinate infants under one year of age against diphtheria, tetanus, pertussis (whooping cough), hepatitis B and ‘invasive' diseases caused by Hib (such as bacterial meningitis). 
Cepivo Quintanrix se uporablja za cepljenje otrok, mlajših od enega leta, proti davici, tetanusu, oslovskemu kašlju, hepatitisu B in „invazivnim“ boleznim, ki jih povzroča Hib (kot je bakterijski meningitis).
The fifth study looked at the effects of a fourth, booster dose of Quintanrix in the second year of life in 357 infants. 
V peti študiji so pri 357 dojenčkih preučevali učinke četrtega, obnovitvenega odmerka cepiva Quintanrix v drugem letu starosti.
The full EPAR for Quintanrix can be found here. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za cepivo Quintanrix je na voljo tukaj.
The immune system will then be able to produce antibodies more quickly when the person is naturally exposed to the bacteria or viruses. 
Ob naravni izpostavitvi bakterijam ali virusu bo imunski sistem izdelal protitelesa hitreje.
Overall, between 95 and 100% of the infants had protective levels of antibodies to diphtheria, tetanus, pertussis, hepatitis B and Hib, one month after the first vaccination course. 
V prvem mesecu po osnovnem cepljenju je imelo skupno 95 do 100 % dojenčkov zaščitne ravni protiteles proti davici, tetanusu, oslovskemu kašlju, hepatitisu B in Hib.
How has Quintanrix been studied? 
Kako je bilo zdravilo Quintanrix raziskano?
What is Quintanrix? 
Kaj je zdravilo Quintanrix?
What is Quintanrix used for? 
Za kaj se zdravilo Quintanrix uporablja?
How does Quintanrix work? 
Kako zdravilo Quintanrix deluje?
In three studies, the effects of Quintarix were compared with those of the combination of Tritanrix HepB and a vaccine containing Hib: two of these studies involved a total of 1,208 infants who were vaccinated at two, four and six months of age and one involved 294 infants vaccinated at three, four and five months of age. 
V dve študiji je bilo vključenih skupno 1208 dojenčkov, ki so bili cepljeni pri starostih dva, štiri in šest mesecev.
How is Quintanrix used? 
Kako se zdravilo Quintanrix uporablja?
Quintanrix can also be used to boost previous vaccinations against diphtheria, tetanus and pertussis, against hepatitis B or against Hib, when it should be given at least six months after the last dose of the first vaccination course. 
Cepivo Quintanrix se lahko uporablja za obnovitev odziva na prejšnja cepljenja proti davici, tetanusu, oslovskemu kašlju, hepatitisu B in Hib.
Further information on Deferiprone Lipomed can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Nadaljnje informacije za zdravilo Deferiprone Lipomed so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Doses above 100 mg/kg a day are not recommended because of a potentially increased risk of side effects. 
Odmerki nad 100 mg/kg na dan niso priporočljivi zaradi morebitnega povečanja tveganja za neželene učinke.
Over time, the excess iron can damage important organs such as the heart or liver. 
Sčasoma lahko odvečno železo poškoduje pomembne organe, kot so srce ali jetra.
Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect. 
Dve zdravili sta bioekvivalentni, kadar dosegata enake ravni učinkovine v telesu in se zato pričakuje, da bosta imeli enak učinek.
Patients with thalassaemia major need frequent blood transfusions. 
Bolniki s talasemijo major potrebujejo pogosto transfuzijo krvi.
The doctor may interrupt treatment if iron levels in the body get too low. 
Zdravnik lahko prekine zdravljenje, če se ravni železa v telesu spustijo prenizko.
The company also carried out a study that showed that it is ‘bioequivalent' to the reference medicine. 
Podjetje je izvedlo tudi študijo, ki je pokazala, da je zdravilo „bioekvivalentno“ referenčnemu zdravilu.
The usual dose of Deferiprone Lipomed is 75 mg per kilogram body weight each day, divided into three separate doses. 
Običajni odmerek zdravila Deferiprone Lipomed je 75 mg na kilogram telesne mase vsak dan, razdeljenih v tri ločene odmerke.
• on its own, when standard iron chelator treatment cannot be used or is inadequate; 
• samostojno, kadar standardnega zdravljenja s kelatorjem železa ni mogoče uporabiti ali ni ustrezno;
The doctor may adjust the dose of Deferiprone Lipomed depending on the patient's response, which should be measured every two to three months with blood tests. 
Zdravnik lahko prilagodi odmerek zdravila Deferiprone Lipomed glede na bolnikov odziv, ki ga je treba s krvno preiskavo izmeriti vsaka dva do tri mesece.
This helps to correct the iron overload and prevent damage due to excess iron. 
To pomaga odpraviti prenasičenost z železom in preprečevati poškodbe zaradi njegovega presežka.
• in combination with another iron chelator, when treatment with one iron chelator on its own is ineffective or when prevention or treatment of life-threatening conditions requires rapid or intensive correction of iron levels. 
• v kombinaciji z drugim kelatorjem železa, kadar samostojno zdravljenje z enim kelatorjem železa ni učinkovito ali kadar preprečevanje ali zdravljenje življenjsko nevarnih bolezni zahteva hitro ali intenzivno spremembo ravni železa.
It attaches to iron in the body to form a compound that can be excreted by the body, mainly in the urine, and to a lesser extent in the stools. 
Veže se na železo v telesu in pri tem tvori spojino, ki jo telo lahko izloča, predvsem z urinom in v manjši meri z blatom.
What measures are being taken to ensure the safe and effective use of Deferiprone Lipomed? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Deferiprone Lipomed?
This is an inherited disease in which patients are unable to make enough haemoglobin, the protein found in red blood cells that carries oxygen around the body. 
To je dedna bolezen, pri kateri bolniki ne morejo tvoriti dovolj hemoglobina, beljakovine v rdečih krvničkah, ki po telesu prenaša kisik.
Because Deferiprone Lipomed is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Deferiprone Lipomed generično zdravilo in je bioekvivalentno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
The European Medicines Agency concluded that, in accordance with EU requirements, Deferiprone Lipomed has been shown to have comparable quality and to be bioequivalent to Ferriprox. 
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Deferiprone Lipomed primerljivo raven kakovosti in je bioekvivalentno z zdravilom Ferriprox.
Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Ferriprox, and do not need to be repeated for Deferiprone Lipomed. 
Študije o koristih in tveganjih učinkovine pri odobrenih načinih uporabe so že bile izvedene z referenčnim zdravilom Ferriprox, zato jih ni treba ponoviti za zdravilo Deferiprone Lipomed.
When patients receive repeated transfusions, the transfused red cells bring iron into the body. 
Če bolniki prejmejo večkratno transfuzijo, prenesene rdeče krvničke s seboj prinesejo tudi železo.
As for every medicine, the company provided studies on the quality of Deferiprone Lipomed. 
Tako kot za vsako zdravilo je podjetje predložilo študije o kakovosti zdravila Deferiprone Lipomed.
Why is Deferiprone Lipomed authorised in the EU? 
Zakaj je bilo zdravilo Deferiprone Lipomed odobreno v EU?
The company that markets Deferiprone Lipomed will ensure that patients taking the medicine, or their carers, are provided with a reminder card with information on how to take the medicine safely. 
Podjetje, ki trži zdravilo Deferiprone Lipomed, bo zagotovilo, da bodo bolniki, ki jemljejo to zdravilo, ali njihovi skrbniki prejeli opozorilno kartico s podatki o varnem jemanju zdravila.
An overview of Deferiprone Lipomed and why it is authorised in the EU 
Pregled zdravila Deferiprone Lipomed in zakaj je odobreno v EU
Side effects reported with Deferiprone Lipomed are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Deferiprone Lipomed, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Deferiprone Lipomed is an ‘iron chelator' (a substance that attaches to iron) that is used to treat iron overload (an excess of iron in the body) in patients with thalassaemia major. 
Zdravilo Deferiprone Lipomed je „kelator železa“ (snov, ki se veže na železo), ki se uporablja za zdravljenje prenasičenosti z železom (prevelike količine železa v krvi) pri bolnikih s talasemijo major.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Deferiprone Lipomed have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Deferiprone Lipomed upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
This means that Deferiprone Lipomed contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Ferriprox. 
To pomeni, da vsebuje enako učinkovino in deluje na enak način kot „referenčno zdravilo“, ki je že odobreno v EU in se imenuje Ferriprox.
What is Deferiprone Lipomed and what is it used for? 
Kaj je zdravilo Deferiprone Lipomed in za kaj se uporablja?
As for all medicines, data on the use of Deferiprone Lipomed are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Deferiprone Lipomed stalno spremljajo.
What are the benefits and risks of Deferiprone Lipomed? 
Kakšne so koristi in tveganja zdravila Deferiprone Lipomed?
However, the body does not have a natural way of removing excess iron, so it builds up. 
Vendar telo presežne količine železa ne more odstraniti po naravni poti, zato se to kopiči.
For more information about using Deferiprone Lipomed, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Deferiprone Lipomed glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Other information about Deferiprone Lipomed 
Druge informacije o zdravilu Deferiprone Lipomed
The active substance in Deferiprone Lipomed, deferiprone, is an iron chelator. 
Učinkovina zdravila Deferiprone Lipomed, deferipron, je kelator železa.
Deferiprone Lipomed can only be obtained with a prescription and treatment should be started and maintained by a doctor who has experience in the treatment of patients with thalassaemia. 
Predpisovanje in izdaja zdravila Deferiprone Lipomed je le na recept, zdravljenje z njim pa lahko uvede in nadzoruje le zdravnik z izkušnjami z zdravljenjem bolnikov s talasemijo.
Deferiprone Lipomed contains the active substance deferiprone and is a ‘generic medicine'. 
Zdravilo Deferiprone Lipomed vsebuje učinkovino deferipron in je „generično zdravilo“.
Deferiprone Lipomed is available as 500 mg tablets to be taken by mouth. 
Na voljo je v obliki 500-miligramskih tablet, ki se jemljejo peroralno.
How has Deferiprone Lipomed been studied? 
Kako je bilo zdravilo Deferiprone Lipomed raziskano?
Therefore, the Agency's view was that, as for Ferriprox, the benefit of Deferiprone Lipomed outweighs the identified risk and it can be authorised for use in the EU. 
Zato je agencija menila, da koristi zdravila Deferiprone Lipomed, enako kot pri zdravilu Ferriprox, odtehtajo znana tveganja in se zdravilo lahko odobri v EU.
Deferiprone Lipomed is used: 
Zdravilo Deferiprone Lipomed se uporablja:
How is Deferiprone Lipomed used? 
Kako se zdravilo Deferiprone Lipomed uporablja?
How does Deferiprone Lipomed work? 
Kako zdravilo Deferiprone Lipomed deluje?
* Withdrawal period (milk): - Zero hours after calving (when the dry period length is 32 days or more) - 4 days (8 milkings) after calving (when the dry period length is less than 32 days) 
* Karenca (mleko): - Nič ur po telitvi (ko je doba presušitve 32 dni ali več) - 4 dni (8 molž) po telitvi (ko je doba presušitve manj kot 32 dni)
Annex A EU (MA) Number Invented name 
EU (MA) številka Izmišljeno ime
Cattle (dairy cows) 
Govedo (krave molznice)
5 vials Meat and offal: 23 days 
Meso in organi: 23 dni
Packaging Content Package size 
Način uporabe Pakiranje Vsebina Velikost pakiranja
Solution for injection 
Raztopina za injiciranje
Route of administration 
5 vial
More information on the orphan designation can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation. 
Več informacij o zdravilih sirotah je na voljo tukaj: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The applicant requested a re-examination of the opinion. 
Vlagatelj je zahteval ponovni pregled mnenja.
What consequences does this refusal have for patients in clinical trials or compassionate use programmes? 
Kakšne so posledice zavrnitve za bolnike, ki sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe?
After considering the grounds for this request, the CHMP re-examined the initial opinion and confirmed the refusal of the marketing authorisation on 1 April 2016. 
Po proučitvi razlogov za to zahtevo je odbor CHMP ponovno pregledal prvotno mnenje in dne 1. aprila 2016 potrdil zavrnitev vloge za dovoljenje za promet.
The Committee confirmed the opinion that the effectiveness of Dropcys in the treatment of corneal deposits had not been sufficiently demonstrated and that there were unresolved issues regarding the formulation and long-term safety and sterility of the medicine. 
Odbor je potrdil mnenje, da učinkovitost zdravila Dropcys pri zdravljenju depozitov v roženici ni bila zadostno dokazana in da obstajajo nerešena vprašanja v zvezi s formulacijo, varnostjo pri dolgoročni uporabi in sterilnostjo zdravila.
What is Dropcys? 
Kaj je zdravilo Dropcys?
During the re-examination, the CHMP looked again at the data from the company. 
Odbor CHMP je pri ponovnem pregledu spet pregledal podatke družbe.
The CHMP considered that the studies from the medical literature presented to support the application were insufficient. 
Odbor CHMP je menil, da so študije iz medicinske literature, predstavljene v podporo vlogi, nezadostne.
In addition, the CHMP had concerns regarding other ingredients of the medicine, their impact on long-term safety, particularly in children, and how stable and sterile the solution would be once prepared. 
Poleg tega je imel odbor CHMP zadržke glede drugih sestavin zdravila, njihovega učinka na varnost pri dolgoročni uporabi, zlasti pri otrocih, ter stabilnosti in sterilnosti raztopine po pripravi.
Although the role of mercaptamine eye drops in the treatment of corneal deposits appears sufficiently supported by the literature, current clinical recommendations and its routine use in hospital preparations, there were few data supporting the effectiveness of the concentration of mercaptamine used in Dropcys (0.1% solution). 
Čeprav vlogo merkaptamina v obliki kapljic za oči pri zdravljenju oblog roženice v zadostni meri podpira literatura, trenutna klinična priporočila in rutinska uporaba bolnišničnih pripravkov, je malo podatkov, ki podpirajo učinkovitost koncentracije merkaptamina, uporabljene v zdravilu Dropcys (0,1 % raztopina).
The build-up of cystine crystals inside corneal cells can damage the eyes and cause serious vision problems. 
Kopičenje kristalov cistina v celicah roženice lahko poškoduje oči in povzroči hude težave z vidom.
Because mercaptamine has been used for many years to treat cystinosis and its use is well established, the applicant presented data from the medical literature to support its application for Dropcys. 
Ker se merkaptamin uporablja že vrsto let za zdravljenje cistinoze in je njegova uporaba dobro uveljavljena, je predlagatelj v podporo svoji vlogi za zdravilo Dropcys predstavil podatke iz medicinske literature.
The company informed the CHMP that there are no ongoing clinical trials or compassionate use programmes with Dropcys. 
Družba je odbor CHMP obvestila, da trenutno ne potekajo klinična preskušanja ali programi sočutne uporabe zdravila Dropcys.
Dropcys is a medicine that contains the active substance mercaptamine hydrochloride (also known as cysteamine hydrochloride). 
Dropcys je zdravilo, ki vsebuje zdravilno učinkovino merkaptaminijev hidroklorid (znan tudi kot cisteaminijev hidroklorid).
Cystinosis is a rare inherited disease caused by the accumulation of a substance called cystine, which forms crystals inside cells, particularly cells in the cornea and kidneys. 
Cistinoza je redka dedna bolezen, ki nastane kot posledica kopičenja snovi, imenovane cistin, ki tvori kristale v celicah, zlasti v celicah roženice in ledvic.
Dropcys was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 15 October 2014 for the treatment of cystinosis. 
Zdravilo Dropcys je bilo dne 15. oktobra 2014 določeno kot »zdravilo sirota« (zdravilo za zdravljenje redkih boleznih) za zdravljenje cistinoze.
Medicines containing mercaptamine hydrochloride are authorised in the EU for use by mouth in the treatment of cystinosis. 
Zdravila, ki vsebujejo merkaptaminijev klorid so dovoljena v EU za peroralno uporabo pri zdravljenju cistinoze.
On 17 December 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Dropcys, intended to prevent and treat the build-up of the amino acid cystine in the cornea (the transparent layer in front of the eye).The company that applied for authorisation in the EU is Lucane Pharma. 
Dne 17. decembra 2015 je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel negativno mnenje in priporočil zavrnitev dovoljenja za promet z zdravilom Dropcys, namenjenim preprečevanju in zdravljenju kopičenja aminokisline cistina v roženici (prozorne plasti na prednji strani očesa).